GRAIL, Inc. (GRAL): Shareholders' Equity
$2.58B
As of 2025-12-31
$2.54B
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.58B | +3.0% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $2.50B | n/a | 2026-03-12, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| GRAIL, Inc. (GRAL) | 2025-12-31 | $2.58B | +3.0% |
| Biodesix Inc (BDSX) | 2025-12-31 | -$2.46M | n/m |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $480.11M | n/m |
| Personalis, Inc. (PSNL) | 2025-12-31 | $261.19M | +28.7% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $1.11B | -1.9% |
| Exagen Inc. (XGN) | 2025-12-31 | $17.45M | +82.9% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $470.87M | +3.3% |
| CareDx, Inc. (CDNA) | 2025-12-31 | $303.10M | -19.9% |
| Veracyte, Inc. (VCYT) | 2025-12-31 | $1.31B | +11.4% |
Compare GRAL, BDSX, BLLN, PSNL side by side · Screen every company in Services-Medical Laboratories ↗